Circadian Rhythm Disruption as a Driver of Tumor Aggressiveness: Chrono Oncology Based Treatment Strategies

Sayma Nasrin Shompa

doi:10.59890/ijaamr.v3i9.107

Authors

Sayma Nasrin Shompa International Islamic University

DOI:

https://doi.org/10.59890/ijaamr.v3i9.107

Keywords:

Circadian Rhythm, Chrono-Oncology, Tumor Aggressiveness, Cancer Chronotherapy, Biological Clock

Abstract

The circadian rhythm, which is governed by superchiasmatic nucleus (SCN) and peripheral oscillator, controls many physiological processes, including cell cycle progress, DNA repair and immune monitoring. The disintegration of this rhythm, whether lifestyle factors, genetic changes, or environmental stimuli, is implicated in the progression of oncogenes and tumor. Recent progress in chrono-acquisition highlights the ability to align cancer treatments with circadian biology to increase efficacy and reduce toxicity. This paper reviews mechanically relations between circadian disintegration and tumor aggression and examines chrono-modulated treatment strategies for individual oncology care. Circadian rhythm, which is orchestrated by superchiasmatic nucleus and peripheral oscillator, is integral to regulate cellular proliferation, DNA repair and immune defense. The disintegration of these rhythms - through genetic mutation, lifestyle patterns, or environmental stresses - is rapidly recognized as the driver of tumor initiation and progress. The task examines the mechanical routes connecting circadian disagrees to increase the aggression of the tumor, including genomic instability, impaired immune monitoring, and converted hormonal balance. The emerging region of chrono-imagology is emphasized, which takes advantage of temporary biology to adapt to cancer treatments. Strategies such as Circadian-Man-Charan-specific chemotherapy administration, biomarker-directed treatment scheduling, and molecular clock-goal agents are reviewed, while reducing toxicity and reviewing for their ability to maximize medical efficacy by reducing poisoning. By integrating insight from pharmacokinetic, pharmacodynamics and translation oncology, this study underlines the need to align treatment with a patient's biological clock. To overcome the challenges of clinical implementation, it will be important to translate chrono-oncology from research in mutual variability and limited biomarker verification-naval clinical practice in the circadian phase. Recent progress in chrono-acquit sheds light on the ability to align cancer treatment with Circadian biology

References

A. B. Chan et al., "Wearable technology for real-time circadian monitoring in cancer patients," Sensors, vol. 21, no. 19, p. 6512, 2021. doi: 10.3390/s21196512.

A. Ballesta et al., "Personalized chronotherapy via wearable biosensors," NPJ Digit. Med., vol. 4, no. 1, p. 98, 2021. doi: 10.1038/s41746-021-00476-7.

A. E. Hoffman et al., "Melatonin receptor agonists in cancer therapy," Trends Pharmacol. Sci., vol. 44, no. 5, pp. 301–315, 2023. doi: 10.1016/j.tips.2023.03.001.

A. Gupta et al., "Circadian reprogramming of tumor-associated macrophages," Immunity, vol. 56, no. 6, pp. 1237–1251, 2023. doi: 10.1016/j.immuni.2023.05.004.

A. Knutsson et al., "Shift work and gastrointestinal cancers: A 10-year follow-up," Occup. Environ. Med., vol. 80, no. 3, pp. 163–170, 2023. doi: 10.1136/oemed-2022-108526.

A. Sancar et al., "Circadian regulation of chemotherapy toxicity," Proc. Natl. Acad. Sci. U.S.A., vol. 120, no. 18, p. e2211506120, 2023. doi: 10.1073/pnas.2211506120.

B. Zhu et al., "BMAL1-deficient macrophages promote tumor metastasis," Cell Rep., vol. 41, no. 5, p. 111573, 2022. doi: 10.1016/j.celrep.2022.111573.

C. R. Cederroth et al., "Circadian desynchrony and metabolic syndrome," Nat. Rev. Endocrinol., vol. 20, no. 2, pp. 75–88, 2024. doi: 10.1038/s41574-023-00898-1.

C. Vetter et al., "Circadian disruption and metabolic dysfunction in shift workers," Diabetes Care, vol. 45, no. 10, pp. 2387–2395, 2022. doi: 10.2337/dc22-1028.

D.-J. Dijk et al., "Circadian disruption and human health," N. Engl. J. Med., vol. 388, no. 18, pp. 1721–1732, 2023. doi: 10.1056/NEJMra2201336.

E. Gottlieb et al., "Tumor-specific circadian biomarkers via liquid biopsy," Nat. Commun., vol. 14, no. 1, p. 4321, 2023. doi: 10.1038/s41467-023-39965-6.

F. Gachon et al., "The circadian clock as a cancer therapeutic target," Science, vol. 374, no. 6568, pp. 648–654, 2021. doi: 10.1126/science.abd6453.

F. Levi et al., "Chrono-FLOIRI regimen in metastatic colorectal cancer: Phase II results," Ann. Oncol., vol. 35, no. 1, pp. 89–98, 2024. doi: 10.1016/j.annonc.2023.10.003.

F. Levi et al., "Circadian timing of anticancer drug delivery systems," Adv. Drug Deliv. Rev., vol. 192, p. 114642, 2023. doi: 10.1016/j.addr.2022.114642.

F. W. Turek et al., "Circadian disruption and cardiometabolic cancer risk," Circ. Res., vol. 132, no. 11, pp. 1429–1444, 2023. doi: 10.1161/CIRCRESAHA.123.321687.

F. Wei et al., "Circadian disruption and prostate cancer incidence in the UK Biobank," Brit. J. Cancer, vol. 127, no. 5, pp. 914–921, 2022. doi: 10.1038/s41416-022-01852-0.

G. Mazzoccoli et al., "Chrono-oncology clinical trial design," Cancers, vol. 13, no. 11, p. 2761, 2021. doi: 10.3390/cancers13112761.

G. Sulli et al., "Circadian regulation of DNA repair in cancer," Cell Rep., vol. 39, no. 7, p. 110819, 2022. doi: 10.1016/j.celrep.2022.110819.

G. Sulli et al., "Pharmacological targeting of circadian transcriptional networks," Cell Chem. Biol., vol. 30, no. 3, pp. 278–291, 2023. doi: 10.1016/j.chembiol.2022.10.003.

G. Wu et al., "CLOCK/BMAL1 regulates genomic stability in pancreatic cancer," Cancer Cell, vol. 40, no. 2, pp. 196–211, 2021. doi: 10.1016/j.ccell.2021.07.008.

IARC Working Group, "Shift work and light at night: Updated carcinogenicity assessment," Lancet Oncol., vol. 24, no. 6, pp. e232–e241, 2023. doi: 10.1016/S1470-2045(23)00188-3.

J. B. Hogenesch et al., "Therapeutic targeting of circadian clock components," Pharmacol. Ther., vol. 248, p. 108454, 2023. doi: 10.1016/j.pharmthera.2023.108454.

J. Bass et al., "Time-restricted feeding and cancer outcomes," JAMA Oncol., vol. 9, no. 4, pp. 512–519, 2023. doi: 10.1001/jamaoncol.2022.6083.

J. Richards et al., "CRY2 stabilization promotes tumor growth in lung adenocarcinoma," J. Clin. Invest., vol. 132, no. 15, p. e156374, 2022. doi: 10.1172/JCI156374.

J. S. Takahashi, "Molecular architecture of the mammalian circadian clock," Nat. Rev. Mol. Cell Biol., vol. 23, no. 4, pp. 227–241, 2022. doi: 10.1038/s41580-021-00418-9.

K. A. Lamia et al., "AMPK regulates circadian clock stability," Mol. Cell, vol. 81, no. 18, pp. 3689–3702, 2021. doi: 10.1016/j.molcel.2021.07.012.

K. B. Koronowski et al., "CK1δ/ε inhibitors resynchronize circadian clock and tumor suppression," Sci. Transl. Med., vol. 15, no. 684, p. eabo4539, 2023. doi: 10.1126/scitranslmed.abo4539.

K. Papantoniou et al., "Night shift work and breast cancer risk: A meta-analysis of 14 cohort studies," Cancer Epidemiol., vol. 84, p. 102356, 2023. doi: 10.1016/j.canep.2023.102356.

L. A. Solt et al., "Development of synthetic circadian modulators," J. Med. Chem., vol. 67, no. 4, pp. 2521–2535, 2024. doi: 10.1021/acs.jmedchem.3c02343.

L. S. Mure et al., "Peripheral circadian clocks in tumor stroma," Nat. Cell Biol., vol. 26, no. 2, pp. 198–210, 2024. doi: 10.1038/s41556-023-01312-8.

M. E. Hughes et al., "AI-driven chronotherapy optimization platforms," Nat. Biomed. Eng., vol. 7, no. 8, pp. 987–1001, 2023. doi: 10.1038/s41551-023-01038-w.

M. H. Hastings et al., "Circadian rhythms in health and disease," Science, vol. 372, no. 6545, p. eabd0823, 2021. doi: 10.1126/science.abd0823.

N. Cermakian et al., "Clock genes and cancer immunity," J. Immunother. Cancer, vol. 9, no. 7, p. e002926, 2021. doi: 10.1136/jitc-2021-002926.

N. Koike et al., "Transcriptional architecture of the circadian clock in cancer," Cell Metab., vol. 33, no. 9, pp. 1762–1777, 2021. doi: 10.1016/j.cmet.2021.08.012.

N. M. Kettner et al., "Circadian dysregulation promotes metastasis via immune evasion," Nat. Cancer, vol. 4, no. 4, pp. 456–471, 2023. doi: 10.1038/s43018-023-00526-x.

N. Ozturk et al., "REV-ERBα agonists induce tumor-specific apoptosis," Cell Death Differ., vol. 29, no. 7, pp. 1436–1449, 2022. doi: 10.1038/s41418-022-00928-x.

P. Crosby et al., "Insulin/IGF-1 drives circadian disruption in tumors," Nat. Commun., vol. 13, no. 1, p. 6074, 2022. doi: 10.1038/s41467-022-33709-8.

P. Pevet et al., "Melatonin: From chronobiotic to anti-cancer agent," Endocr. Rev., vol. 45, no. 1, pp. 1–28, 2024. doi: 10.1210/endrev/bnad028.

R. C. Anafi et al., "Machine learning for circadian phenotyping in oncology," Cell Syst., vol. 15, no. 5, pp. 380–391, 2022. doi: 10.1016/j.cels.2022.04.002.

R. Dallmann et al., "Chrono-PK/PD modeling of oxaliplatin in metastatic cancer," Clin. Pharmacol. Ther., vol. 112, no. 3, pp. 634–645, 2022. doi: 10.1002/cpt.2645.

S. Masri et al., "Circadian-hormonal crosstalk in tumor microenvironment remodeling," Trends Endocrinol. Metab., vol. 32, no. 10, pp. 807–819, 2021. doi: 10.1016/j.tem.2021.07.002.

S. Panda, "Chrono-nutrition and cancer prevention," Annu. Rev. Nutr., vol. 44, pp. 121–143, 2024. doi: 10.1146/annurev-nutr-062322-021140.

S. Sahar et al., "Metabolic oscillations in tumor cells," Nat. Metab., vol. 4, no. 12, pp. 1650–1663, 2022. doi: 10.1038/s42255-022-00679-6.

S. Sato et al., "CRISPR screens identify clock genes as synthetic lethal targets in p53-mutant cancers," Cell Metab., vol. 36, no. 1, pp. 88–102, 2024. doi: 10.1016/j.cmet.2023.11.010.

T. Karantanos et al., "Circadian clock modulation of checkpoint inhibitors," Cancer Immunol. Res., vol. 11, no. 6, pp. 730–745, 2023. doi: 10.1158/2326-6066.CIR-22-0654.

V. Blakeman et al., "Chrono-radiotherapy: A systematic review," Radiother. Oncol., vol. 163, pp. 219–230, 2021. doi: 10.1016/j.radonc.2021.08.019.

W. Ruan et al., "Circadian gene PER2 suppresses glioblastoma progression," Cancer Res., vol. 82, no. 20, pp. 3718–3732, 2022. doi: 10.1158/0008-5472.CAN-22-0099.

X. Li et al., "Chrono-modulated chemotherapy in colorectal cancer: A phase III trial," J. Clin. Oncol., vol. 41, no. 15, pp. 2801–2812, 2023. doi: 10.1200/JCO.22.02812.

Y. Lee et al., "Melatonin suppresses tumor angiogenesis via circadian clock modulation," J. Pineal Res., vol. 73, no. 1, p. e12802, 2022. doi: 10.1111/jpi.12802.

Z. Chen et al., "Rev-erbα agonists synergize with immunotherapy in triple-negative breast cancer," Cancer Discov., vol. 12, no. 8, pp. 1940–1957, 2022. doi: 10.1158/2159-8290.CD-21-1320.